Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR

Watchlist Manager
Arrowhead Pharmaceuticals Inc Logo
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Watchlist
Price: 18.54 USD 1.42% Market Closed
Market Cap: 2.3B USD
Have any thoughts about
Arrowhead Pharmaceuticals Inc?
Write Note

Operating Margin
Arrowhead Pharmaceuticals Inc

-2 785.1%
Current
-392%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 785.1%
=
Operating Profit
-547.2m
/
Revenue
19.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
2.3B USD
-2 785%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-22%
Country US
Market Cap 2.3B USD
Operating Margin
-2 785%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.7B USD
Operating Margin
28%
Country US
Market Cap 158.3B USD
Operating Margin
19%
Country US
Market Cap 115.9B USD
Operating Margin
40%
Country US
Market Cap 112.4B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.5B EUR
Operating Margin
-22%
No Stocks Found

Arrowhead Pharmaceuticals Inc
Glance View

Market Cap
2.3B USD
Industry
Biotechnology

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 329 full-time employees. The firm uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The firm's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

ARWR Intrinsic Value
27.97 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 785.1%
=
Operating Profit
-547.2m
/
Revenue
19.6m
What is the Operating Margin of Arrowhead Pharmaceuticals Inc?

Based on Arrowhead Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -2 785.1%.